HGH Injections For Sale

For clients like Charlie whove began experiencing first woman or mens the age of puberty, hormone blockers can be the 1st solution.

Once an individual has begin or done adolescence, getting proposed hormones helps customers correspond to their health with regards to sex identities. Almost certainly my own people, Zoe, happens to be an 18-year-old transgender woman whos got currently done male puberty. The woman is taking oestrogen and a medication to bar the consequences of libido. Together, these should help Zoes body demonstrate breasts, minimize new hair growth and get a general much more feminine structure.

Medical risk from taking hormones are extremely smallest maybe not considerably various, in fact, versus danger a cisgender people experiences from the human hormones within their entire body. Some recommended hormones impact become partly reversible, but others tend to be more long-term, like express deepening and growth and development of undesired facial hair or breasts. Hormones may results virility, thus I be sure your customers along with their people understand the system carefully.

Likely the most permanent medical options offered happen to be gender-affirming operations. These surgery can include modifications to genitals, breasts or tits and facial build. Operations are not quite easily reversible, so my co-workers and I always make sure that clients fully understand this decision. A lot of people believe gender-affirming surgeries proceed far and therefore minors are way too young in order to make this an enormous commitment. But based on readily available investigation and my own adventure, people exactly who put these treatments feel changes as part of the total well being through a decrease in dysphoria. I have been told through customers that gender-affirming surgery literally saved living. I Found Myself no-cost [from dysphoria].

In March 2021, nearly 5 years after our personal primary check out, Charlie stepped into simple exam place. When we for starters found, he was being affected by their sex, anxiousness and melancholy. This time around, the guy immediately moving discussing enjoying hockey, hanging out with associates and making the honor move. He has recently been on hormones blockers for 5 decades and testosterone for nearly 12 months. By using a supportive kids and a gender-competent counselor, Charlie has grown Niche dating site to be growing.

Getting transgender isnt whatever disappears completely. Its something our patients tolerate with regards to their entire everyday lives. Our multidisciplinary attention group continues to notice individuals like Charlie regularly, usually following them into youthful maturity.

While more scientific studies are constantly demanded, a gender-affirmative strategy and evidence-based treatments allows young transgender individuals to reside in the planet since their reliable selves. This increases well being and helps you to save lives, among our very own transgender individuals stated about his adventure getting gender-affirming care and attention.

I in all honesty dont think I would be around received we not just become permitted to transition when this occurs. Im not at all times 100per cent. But You Will Find anticipate. Now I Am very happy to find out tomorrow and I also see I will acquire my personal goals.

On October 29, 2019 Senate Bill 20 plummeted into impact. Under this guidelines, individuals who comprise originally from New Mexico and would like to change up the gender designation as well as the sex designation regarding youngster the beginning certification to do so by completing the correct demand type with the Bureau of Vital Records. The latest rules will allow for Mens, feminine and times as appropriate options. X means a gender rather than male or female or an, undesignated gender.

Read the original post:

For clients like Charlie who've began experiencing first woman or mens the age of puberty, hormone blockers can be the 1st solution. - ADOTAS

I-Mab to host conference calls and webcasts on August 31, 2021. A Mandarin session conference call will be held at 7:00 a.m. ET, and an English session conference call will be held at 8:00 a.m. ET.

SHANGHAI and GAITHERSBURG, Md., Aug. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced financial results for the six months ended June 30, 2021, and provided key business updates.

During the reporting period, I-Mab has made remarkable progress in its key business areas. Firstly, on the R&D front, the Company has rapidly advanced its globally competitive pipeline and achieved all critical clinical milestones as set in early 2021 for the key pipeline assets. More specifically, the Company had seven clinical trials initiated or soon to be initiated, achieved five key data readout events for its differentiated investigational drugs, i.e. CD38 antibody felzartamab (TJ202/MOR202), CD47 antibody lemzoparlimab (TJC4), CD73antibody uliledlimab (TJD5), GM-CSF antibody plonmarlimab (TJM2) and novel IL-6 inhibitor olamkicept (TJ301). Furthermore, the Company has made significant progress in expanding the current pipeline through the bi-specific antibody panel, where two lead assets have advanced to clinical trials in the U.S. in early 2021, as well as the next generation of novel antibody candidates enabled by transformative technologies through collaborations. In this regard, the Company has successfully entered into five technology partnering deals to gain access to cutting-edge technologies to generate novel drug molecules with uniquely acquired drug properties, including mRNA delivery, AI-guided targeting, cell-penetrating antibody and tumor-site activation. Secondly, on the corporate development front, the Company has met all expected corporate milestones with respect to building its manufacturing facility in Hangzhou and its commercialization capabilities and preparation of the market launch of felzartamab. I-Mab is now globally connected with six sites or offices in China and two R&D facilities in the U.S. Thirdly, during the reporting period, the Company has initiated its dual listing plan for the STAR Market in China and received multiple prestigious corporate honors by the global biotech community and the capital market. The Company also made efforts to further strengthen its Board of Directors and Scientific Advisory Board with internationally reputable experts.

"With the corporate focus and execution by our highly committed team, I-Mab has managed to have successfully delivered outstanding results that have exceeded our original expectations set early this year," said Dr. Jingwu Zang, Founder and Chairman of I-Mab. "We are thrilled by the achievements because many of the milestones are critical as they have provided positive and enabling clinical data needed for the further development of the key pipeline assets. Looking ahead, we will have 19 clinical trials either ongoing or soon to be initiated in both the United States and China by the end of this year, including our first BLA submission in Q4 2021. With these achievements, our pipeline is now not only innovative and globally competitive but also advanced with more assets moving towards late-stage clinical trials and BLA."

"The progress we have made so far has placed us firmly on track to deliver the rest of the critical milestones and has effectively secured our overall development plan for the key assets such as felzartamab, eftansomatropin alfa, lemzoparlimab, uliledlimab, and plonmarlimab. We are very excited and confident to succeed in our journey to transition from a clinical stage biotech now to a global biopharma within the next few years," Dr. Zang concluded.

Recent Pipeline Highlights and Upcoming Milestones

I-Mab has completed felzartamab 3L registrational trial, enabling the Company's first BLA submission in Q4 2021, and currently manages two additional registrational trials, sevenPhase 2 and eightPhase 1 clinical studies that are either ongoing or soon to be initiated in the U.S. and China. In parallel, a series of pre-clinical programs representing the next generation of innovative assets, i.e. bi-specific antibodies as well as so called "super antibodies", are under the development and some will advance towards IND application in 2022.

Rapidly Advancing Clinical Development of the Late-Stage Assets for Near-Term Value Creation

(1) Phase 3/pre-BLA assets

Felzartamab (TJ202/MOR202): A differentiated CD38 antibody for the treatment of multiple myeloma (MM) and potentially autoantibody-mediated autoimmune diseases such as systemic lupus erythematosus (SLE). I-Mab has licensed development, manufacturing and commercialization rights for felzartamab in Greater China from MorphoSys.

Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021 and MM second-line registrational trial is on track. The Company plans to submit a new IND application in Q3 2021 to explore the combination of felzartamab with another I-Mabclinical asset as a potential first-line treatment for MM. The rationale of this combination study is strongly supported by the pre-clinical evidence.

Eftansomatropin alfa (TJ101): A differentiated long-acting growth hormone for pediatric growth hormone deficiency (PGHD). Eftansomatropin alfa is the only rhGH in its proprietary fusion protein format (pure protein-based molecule) and is not chemically linked with PEG or other linkers. Its safety, tolerability, and efficacy have been well demonstrated in a phase 2 clinical trial in the EU. I-Mab has the development, manufacturing, and commercial rights of eftansomatropin alfa in China from Genexine.

(2) Core clinical assets

Lemzoparlimab (TJC4): A highly differentiated CD47 antibody being developed through a comprehensive clinical development plan for hematologic malignancies and solid tumors in China by I-Mab and globally by AbbVie. I-Mab's goal is to achieve the first registration of lemzoparlimab in its class in China and facilitate global registration in collaboration with AbbVie, which leads global development and commercialization efforts. To achieve this goal, three clinical programs of lemzoparlimab are ongoing in parallel in both the U.S. and China, which will potentially lead to one or two pivotal clinical trials in 2022.

Uliledlimab (TJD5): A highly differentiated CD73 antibody being developed for solid tumors. Phase 1 clinical trial conducted in the U.S. was completed and the clinical data was presented at ASCO 2021 as described below. The Company is advancing the asset in phase 2 clinical trials in both the U.S. and China in selected tumor types in an effort to demonstrate clinical proof-of-concept. In parallel, the Company is exploring a potential global partnering deal.

Plonmarlimab (TJM2): A monoclonal antibody targeting human granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that plays a critical role in acute and chronic inflammation. The Company recently carried out an interim analysis of its phase 2/3 clinical trial for the treatment of cytokine release syndrome (CRS) in patients with severe COVID-19 in the U.S. The results are reported below.

Efineptakin alfa (TJ107): The world's first and only long-acting recombinant human interleukin-7 ("rhIL-7"). This asset is clinically positioned as a monotherapy for the treatment of cancer patients with lymphopenia and as a combination immunotherapy with a PD-1 or PD-L1 antibody for cancer treatment. I-Mab has the development, manufacturing, and commercial rights of efineptakin alfa in Greater China from Genexine.

I-Mab is accelerating the clinical development of efineptakin alfa by leveraging accumulative clinical data from multiple previous studies either as a monotherapy or in combination with checkpoint inhibitors in cancer patients, as conducted by I-Mab in China and Genexine and NeoImmuneTech in South Korea and the U.S., respectively.

(3) Other clinical assets

Olamkicept (TJ301): A differentiated IL-6 blocker for ulcerative colitis and other autoimmune diseases. I-Mab entered into a license agreement with Ferring Pharmaceuticals to develop and commercialize olamkicept for Greater China and South Korea in 2016. On April 23, 2021, the Company and Ferring signed a memorandum of understanding (MoU) to explore a possible collaboration to advance the development and commercialization of olamkicept in US and Canada, the European Union and Japan, if so agreed.

Enoblituzumab (TJ271): A humanized B7-H3 antibody as an immuno-oncology treatment agent. As an anti-tumor agent, enoblituzumab works through a unique dual mechanism, i.e. ADCC and immune activation. Over the years, MacroGenics has generated sufficient clinical data in cancer patients, which provide a critical guidance for further clinical development of enoblituzumab in the treatment of cancers. In addition, I-Mab's in-house work is geared towards delineating the combo strategy where enoblituzumab in combination with another treatment agent achieves synergism required for increased clinical efficacy. The Company's development strategy is to move ahead with a combination therapy with pembrolizumab (Keytruda) in selected cancer types, followed by new combo studies with other validated anti-tumor agent(s). I-Mab licensed the development, manufacturing, and commercialization rights of enoblituzumab in Greater China from MacroGenics.

TJ210: A novel monoclonal antibody targeting C5aR1 to treat cancers through myeloid-derived suppressor cells and modulation of tumor micro-environment in favor of enhanced anti-tumor immune response as a novel mechanism of action. The pre-clinical studies have provided ample scientific evidence for the role of TJ210 in the treatment of cancers. Research is continuing, through in vitro and in vivo experimental systems, to identify and validate the most effective combo partner(s) for TJ210 to guide further clinical development of TJ210. I-Mab owns the China rights from MorphoSys and co-develop the asset globally with MorphoSys.

Pipeline New-Comers as Bi-Specific Antibodies Driven by 2nd Wave Innovation and as "Super Antibodies" by 3rd Wave Innovation Through Transformative Technologies

(1) Bi-Specific Antibodies

The Company's bispecific antibodies are novel and designed to address the current unmet medical need in oncology where the majority of cancer patients respond poorly to checkpoint inhibitors as their tumors are often characterized as immunologically 'cold' tumor type. I-Mab's bi-specific antibodies are structurally and functionally enabled to convert immunologically resistant 'cold' tumors to immunologically responsive 'hot' tumors by targeting multiple immune pathways so as to achieve synergistic anti-tumor activities. They can be categorized into three antibody formats, namely PD-L1-based bispecific antibodies, 4-1BB-based conditional T cell engagers, and antibody-cytokine fusion or so-called immuno-cytokines. During the reporting period, two lead bi-specific antibody assets have advanced to Phase 1 clinical trials in the U.S.

TJ-CD4B: A novel Claudin 18.2 and 4-1BB bispecific antibody capable of binding to tumor cells expressing Claudin 18.2, i.e., gastric cancer and pancreatic cancer cells, and stimulating intra-tumoral T cells by the 4-1BB arm designed to become functionally active only upon tumor engagement whilst silent elsewhere.

In June2021, the first patient was dosed in a phase 1 clinical trial of TJ-CD4B in patients with advanced or metastatic solid tumors in the U.S. To accelerate its clinical development, China sites will join the dose expansion part of the study in Q1 2022, enrolling patients with gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, and pancreatic ductal adenocarcinoma.

TJ-L14B: A differentiated PD-L1-based bispecific antibody with the PD-L1 arm as the tumor-dependent T-cell activator and the 4-1BB arm as the conditional T cell activator upon local tumor engagement.

In addition, other novel bispecific antibodies are currently under pre-clinical development and are expected to advance to the clinical studies in 2022, including:

(2) Super Antibodies Enabled by Transformative Technologies

The Company recently launched a discovery initiative (the third wave innovation) to build a new portfolio of next generation of innovative drug candidates characterized as novel "super antibodies". These super antibodies are structurally different from monoclonal or bi-specific antibodies and uniquely enabled by transformative technologies such as an mRNA-based antibody, masked antibody, cell-penetrating antibody and AI-guided cytokine drugs etc. The Company has gained the access to these cutting-edge technology platforms through collaborations as described below. This growing new portfolio of novel drug candidates represents I-Mab's strong commitment to sustaining the global competitiveness of its pipeline through continued innovation and complements the existing clinical programs.

The Company continues to drive innovation and scientific leadership in immuno-oncology globally. These collaborations are expected to be followed by additional partnering deals that are under discussion, which are designed to propel the discovery engine to drive future pipeline growth.

Business Development and Partnering deals

During the reporting period, the Company has completed 7 licensing and partnering deals that are geared to support the next generation of innovative assets. In addition, the Company is in discussion or business negotiation with potential partners on the following opportunities: (1) Eftansomatropin alfa (TJ101) for a commercial partnering deal with a potential partner at a term-sheet stage, for which I-Mab expects to hold MAH and share in significant sales profit; and (2) Other ongoing BD activities, focusing on in-licensing opportunities for the purpose of enriching the Company's initial commercial portfolio. In addition, the Company is exploring a potential global partnering deal with respect to uliledlimab (TJD5) where I-Mab expects to retain the Greater China rights and grant ex-China rights to a potential global partner.

Transitioning from a Clinical Stage Biotech to Become a Global Biopharma

I-Mab has embarked on a journey to evolve from a clinical stage biotech today to a global biopharma within the next three years. The Companyhas been expanding its global R&D and corporate footprint and is now globally connected with six sites or offices in China (Shanghai, Beijing, Hangzhou, Guangzhou, Lishui, and Hong Kong) and two sites in the U.S. (Maryland and San Diego). During the reporting period, the Company has made significant progress in advancing its build-up of the manufacturing facility in Hangzhou and its commercialization capability to prepare for the market launch of felzartamab, which has already started in 2021.

Expanding global footprint

(1) A new R&D facility is being established in San Diego, CA, in the U.S. to focus on translational medicine and biomarker research to support the clinical development of I-Mab pipeline assets in the U.S. and China. The center will also host the CMC formulation research and global alliance management. The facility will be operational in Q4 2021; (2) Opening of a new office in Guangzhou, China as a regional hub for clinical development and commercial activities, further aligning the Company's strategy with the Greater Bay Area ("GBA") initiative. These new sites complement with Company's existing facilities and are designed to facilitate its ambition to become a global biopharma.

Building manufacturing capability in Hangzhou

To support its growing pipeline and planned production of the upcoming commercial products, the Company has made substantial progress in the construction of a state-of-the-art GMP manufacturing facility in Hangzhou, China. The pilot plant with 3 x 2,000L production lines is on track to become operational by mid-2022. The PD laboratory is already functional to handle I-Mab's CMC projects. The commercial production facility is being constructed to accommodate up to 8 x 4,000L production lines and is on track to be operational by the end of 2023 or early 2024. The Hangzhou facility has been designed in compliance with Good Manufacturing Practice (GMP) standards adopted by the U.S. Food & Drug Administration (FDA), the China National Medical Products Administration (NMPA), and European Medicines Agency (EMA).

Expanding the commercialization capability for the market launch of felzartamab and other upcoming products

During the reporting period, the Company has advanced to expand the initial commercialization capability in the following four areas. (1) The key commercial strategy for I-Mab is to leverage its key pipeline products, i.e. felzartamab for multiple myeloma and lemzoparlimab for leukemia, e.g. AML and MDS, and lymphoma when combined with rituximab, to become a leader in the hematologic oncology therapeutic area in China. (2) The current expert commercial core team is being expanded to cover all commercialization functions, including regulatory, market research, market access, reimbursement, sales team etc. The team will be ready for scale up as felzartamab approaches the planned market launch. (3) An integrated multi-functional team consisting of different expertise has been assembled and working towards "preparing the organization", "preparing the market" and "preparing the product" for felzartamab. (4) There are ongoing efforts to enrich the initial product portfolio, beyond felzartamab, through in-licensing and commercial partnering opportunities. Potential deals are expected in late 2021 or early 2022.

ESG Update

In July 2021, I-Mab was granted a BBB rating, the highest newly initiated rating among China-based biotech companies, by the MSCI ESG assessment. In August 2021, the Company established an ESG Committee. The committee consists of Ms. Huaqiong Shen, executive director and CEO of I-Mab, and two independent directors, Mr. Chun Kwok Alan Au and Ms. Rong Shao. Mr. Chun Kwok Alan Au also chairs the committee to ensure impartiality. As the oversight body for the Company's ESG practices, the committee is responsible for supervising the ESG strategies, policies, long-term sustainability objectives and risks of the Company. In addition, the Company also set up an ESG working group to address daily ESG workflows.

I-Mab's vision has been not only to bring innovative therapies to global patients and create value for its shareholders but is also committed to high corporate governance standards, diversity, green operations, sustainable development, and transparent disclosures. Looking forward, the Company will continuously improve its ESG practice and carry out new initiatives to further integrate ESG factors into its strategies and corporate values and communicate periodic progress with investors in a timely manner.

Corporate Development

First-Half 2021Financial Results

Cash Position

As of June 30, 2021, the Company had cash, cash equivalents, restricted cash, and short-term investments of RMB 4.8 billion (US $739.2 million), compared with RMB 4.8billion as of December 31, 2020. Our strong cash balance provides us with adequate funding support and strategic flexibility as we transition from a clinical stage biotech to a global biopharma company over the next few years.

Net Revenues

Total net revenues for the six months ended June 30, 2021 wereRMB 17.8 million (US $2.8 million). The total net revenues for the comparable period in 2020 were nil. Revenues generated for the six months ended June 30, 2021 solely consisted of revenues recognized in connection with I-Mab's strategic collaboration with AbbVie.

Research & Development Expenses

Research and development expenses for the six months ended June 30, 2021 were RMB 593.0 million (US $91.8 million), compared with RMB 442.3million for the six months ended June 30, 2020. The increase was primarily due to increased CRO service fees to advance the Company's broad clinical and pre-clinical pipeline, especially for lemzoparlimab (TJC4), uliledlimab (TJD5), and eftansomatropin alfa (TJ101). Share-based compensation expense was RMB 112.7 million (US $17.5 million) for the six months ended June 30, 2021, compared with RMB 132.7 million for the six months ended June 30, 2020.

Administrative Expenses

Administrative expenses for the six months ended June 30, 2021 were RMB 451.5million (US $69.9million), compared with RMB 171.4million for the six months ended June 30, 2020. The increase was primarily due to higher share-based compensation expenses in relation to management, increased professional service expenses (including expenses that were one-off in nature) and expansion in payroll and payroll-related expenses as a result of increased headcount (including new hires in preparation for product launch and commercialization). Share-based compensation expense was RMB 222.0 million (US $34.4 million) for the six months ended June 30, 2021, compared with RMB 97.1 million for the six months ended June 30, 2020. One-time expenses were RMB 69.9 million (US $10.8 million) for the six months ended June 30, 2021, compared with nil for the six months ended June 30, 2020.

Net Loss

Net loss for the six months ended June 30, 2021 was RMB 1,076.5million (US $166.7 million), compared with RMB 582.9million for the six months ended June 30, 2020. Net loss per share attributable to ordinary shareholders for the six months ended June 30, 2021 was RMB 6.38 (US $0.99), compared with RMB 4.78 for the six months ended June 30, 2020. Net loss per ADS attributable to ordinary shareholders for the six months ended June 30, 2021 was RMB 14.67 (US $2.28), compared with RMB 10.99 for the six months ended June 30, 2020.

Non-GAAP Net Loss

Non-GAAP adjusted net loss, which excludes share-based compensation expenses, for the six months ended June 30, 2021 was RMB 729.4 million (US $113.0million), compared with RMB 353.1 million for the six months ended June 30, 2020. Non-GAAP adjusted net loss per share attributable to ordinary shareholders for the six months ended June 30, 2021 was RMB 4.32 (US $0.67), compared with RMB 2.90 for the six months ended June 30, 2020. Non-GAAP adjusted net loss per ADS attributable to ordinary shareholders for the six months ended June 30, 2021 was RMB 9.94 (US $1.54), compared with RMB 6.67 for the six months ended June 30, 2020.

Conference Call and Webcast Information

The Company's management will host conference calls to discuss the results and updates, and a Mandarin session conference call will be held at 7:00 a.m. ET,and an English session conference call will be held at 8:00 a.m. ET. The conference calls can be accessed by the following Zoom links:

Mandarin Session

English Session

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon, commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global collaborations. The Company is on track to transition from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facilities and commercial capability. I-Mab has offices in Beijing, Shanghai, Hangzhou, Hong Kong and Maryland, United States. For more information, please visit http://ir.i-mabbiopharma.comand follow I-Mab on LinkedIn, Twitterand WeChat.

I-Mab Forward Looking Statements

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Company's clinical developments, commercial and other operations, as well as those risks more fully discussed in the "Risk Factors" section in I-Mab's most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab, and I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Use of Non-GAAP Financial Measures

To supplement its consolidated financial statements which are presented in accordance with U.S. GAAP, the Company uses adjusted net income (loss) as a non-GAAP financial measure. Adjusted net income (loss) represents net income (loss) before share-based compensation. The Company's management believes that adjusted net income (loss) facilitates better understanding of operating results and provide management with a better capability to plan and forecast future periods. For more information on the non-GAAP financial measures, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

Non-GAAP information is not prepared in accordance with GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The presentation of this additional information should not be considered a substitute for GAAP results. A limitation of using adjusted net income (loss) is that adjusted net income (loss) excludes share-based compensation expense that has been and may continue to be incurred in the future.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader.Unless otherwise noted, all translations from Renminbi to U.S. dollars are made at a rate of RMB 6.4566 to US$1.00, the rate in effect as of June 30, 2021 published by the Federal Reserve Board.

For more information, please contact:

I-MabJielun Zhu, Chief Financial OfficerE-mail: [emailprotected]Office line: +86 21 6057 8000

Gigi Feng, Chief Communications OfficerE-mail:[emailprotected] Office line: +86 21 6057 5709

Investor Inquiries:The Piacente Group, Inc. Emilie WuE-mail: [emailprotected]Office line: + 86 21 6039 8363

I-MAB

Consolidated Balance Sheets

(All amounts in thousands, except for share and per share data, unless otherwise noted)

As of December 31,

As of June 30,

2020

2021

RMB

RMB

US$

Assets

Current assets

Cash and cash equivalents

4,758,778

4,341,960

672,484

Restricted cash

-

8,095

1,254

Accounts receivable

130,498

-

Here is the original post:

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021 - PRNewswire

Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from the childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. The affected children develop a characteristic facial experience including prominent eyes, small chin, protruding ears, thin lips and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a loss of fat under the skin (subcutaneous fat). Moreover, patients of Hutchinson-Gilford progeria syndrome experiences severe hardening of the arteries (arteriosclerosis) from the childhood. The condition worsens with age and increases the risk of heart attack or stroke even at a young age.

Get a Sample Copy of the Report at:https://www.coherentmarketinsights.com/insight/request-sample/35

The prominent players in the Hutchinson-Gilford Progeria Treatment Market are Technology & Research (A*STAR)

In 2012, findings of the first clinical trial of the drug Lonafarnib, a farnesyltransferase inhibitor (FTI), gave a new hope for the treatment of children with Hutchinson-Gilford progeria syndrome. Clinical trial results demonstrated improvement in weight gain, increase in bone mineral density, reduced vascular stiffness, and improved sensorineural hearing in patients with progeria. Previous treatments with growth hormone, and Sulforaphane helped in reducing the symptoms, and prolong a childs life. However, it is essential that the patient regularly visits the cardiologist. Rapamycin is one other drug used before, that demonstrated to reverse nuclear blebbing, retard cellular senescence, and facilitate degradation of progerin.

Recently in 2015, the scientists at the Agency for Science, Technology & Research (A*STAR) successfully established a model of Hutchinson-Gilford progeria syndrome. The study conducted by this organization proposed a model which implies that progerin is linked to telomeres. Progerin induces a reduction in heterochromatin, a tightly packed form of DNA, making telomeres in the cell more fragile and susceptible to damage. The damaged telomeres in turn trigger premature cellular aging. This model is radically different from the one believed earlier the gene progerin caused the nucleus to be deformed, thereby weakening the ability of cells to divide and proliferate. The altered progerin protein makes the nuclear envelope unstable and progressively damages the nucleus, making cells more likely to die prematurely.

Buy This Complete A Business Report With Flat US $2000 Off @https://www.coherentmarketinsights.com/promo/buynow/35

Important Features that are under Offering and Key Highlights of Hutchinson-Gilford Progeria Treatment Market Report:

Frequently Asked Questions

Also, Research Report Examines:

Request Here For PDF Brochure:https://www.coherentmarketinsights.com/insight/request-pdf/35

Thanks for reading this article ;you can also get individual chapter-wise sections or region-wise report versions like North America, Europe, or Asia.

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: sales@coherentmarketinsights.comUnited States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

Read more here:

[PDF] Hutchinson-Gilford Progeria Treatment Market to Witness Robust Expansion Throughout by 2027 UNLV The Rebel Yell - UNLV The Rebel Yell

We understand that you may have a lot of questions when your child is diagnosed with growth hormone deficiency. Is it dangerous? Will it affect my child long term? What do we do next? Weve tried to provide some answers to those questions here, and our experts can explain your childs condition fully.

What is growth hormone deficiency?

Growth hormone deficiency is a complex problem that can take different forms from patient to patient.

Growth hormone is a protein produced by the pituitary gland, which is located near the base of the brain and attached to the hypothalamus (a part of the brain that helps to regulate the pituitary gland). If the pituitary gland or the hypothalamus is malformed or damaged, it may mean that the pituitary gland cant produce growth hormone.

If the pituitary gland is lacking in multiple pituitary hormones, the condition is called hypopituitarism.

How do you define "normal" growth?

Growth rates vary considerably from child to child. But measured in height, average "normal" growth is often described as:

If your child is less than the 3rd percentile in height for a child of his age, that can be a red flag for growth hormone deficiency.

Some research suggests that there are additional complications from growth hormone deficiency, including:

Damage to the pituitary gland or hypothalamus may be the result of an abnormal formation that occurred before your child was born (congenital) or something that occurred during or after birth (acquired).

Congenital growth hormone deficiency can occur if there are mutations in genes for factors that are important in pituitary gland development, or in receptors and factors (including growth hormone) along the growth hormone pathway; to date, however, the cause of most of these cases is unknown.

Acquired causes of growth hormone deficiency include:

It's also important to remember that growth hormone deficiency is only one of many conditions that may affect your childs growth. Your childs short stature may be caused by other syndromes, and growth failure may be due to decreased nutritional intake, gastrointestinal disorders, diseases that have increased metabolic demand or hypothyroidism.

Since growth takes place over many years, and since children grow at different rates, symptoms of growth hormone deficiency may be hard to identify. In addition to noticeably slow growth with normal body proportions, signs may include:

Growth hormone deficiency has no affect on a childs intelligence.

These symptoms may resemble other conditions, so be sure to always consult your child's physician for a diagnosis.

Q: What is growth hormone deficiency?

A: Growth hormone is a protein produced by the pituitary gland, which is located near the base of the brain and attached to the hypothalamus (a part of the brain that helps to regulate the pituitary gland). If the pituitary gland or the hypothalamus is malformed or damaged, it may mean that the pituitary gland cant produce growth hormone.

If the pituitary gland is lacking in multiple pituitary hormones, the condition is called hypopituitarism.

Q: What causes growth hormone deficiency?

A: Damage to the pituitary gland or hypothalamus may be the result of an abnormal formation that occurred before your child was born (congenital) or something that occurred during or after birth (acquired).

Your childs short stature may also be caused by other syndromes, and growth failure may be due to decreased nutritional intake, medications, gastrointestinal disorders, diseases that have increased metabolic demand or hypothyroidism.

Q: Is growth hormone deficiency treatable?

A: Treatment of growth hormone deficiency involves regular injections of synthetic human growth hormone. Children receive daily injections. Treatment usually lasts several years, although results are often seen as soon as three to four months after the injections are started.

The earlier the treatment for growth hormone deficiency is started, the better chance the child will have of attaining her normal or near-normal adult height. However, not all children respond well to growth hormone treatment.

Q: How safe is treatment for growth hormone deficiency?

A: While there are many potential side effects, particularly if growth hormone is used to treat children who don't have a true hormone deficiency, researchers generally agree that treatment with human growth hormone is safe and effective.

Q: Will growth hormone deficiency affect my childs intelligence?

A: Growth hormone deficiency has no effect on a childs intelligence.

You and your family are key players in your childs medical care. Its important that you share your observations and ideas with your childs health care provider and that you understand your providers recommendations.

If your child is experiencing symptoms of growth hormone deficiency and youve set up an appointment, you probably already have some ideas and questions on your mind. But at the appointment, it can be easy to forget the questions you wanted to ask. Its often helpful to jot them down ahead of time so that you can leave the appointment feeling like you have the information you need.

If your child is old enough, you may want to suggest that she write down what she wants to ask her health care provider, too.

Some of the questions you may want to ask include:

See more here:

Growth Hormone Deficiency Symptoms & Causes | Boston Children ...

Other names: human growth hormone, somatotropin

Growth hormones are hormones that stimulate growth and cell reproduction and regeneration. They are released naturally by the anterior pituitary gland, a pea-sized gland located at the base of the skull. Growth hormone deficiency (GHD) is more likely to affect children rather than adults and is a symptom of several genetic diseases such as Prader-Willi syndrome and Turner Syndrome. GHD is also more likely in children with cleft lips or palates. Infection, head injuries, and radiation treatment may lead to acquired GHD. Naturally occurring growth hormone is also known as somatotropin.

A synthetic version of growth hormone, somatropin, is used to treat disorders of growth hormone production or deficiency. Symptoms in children include failure to meet height and weight growth standards.

Filter byAll conditionsAdult Human Growth Hormone DeficiencyAIDS Related WastingCachexiaGrowth Hormone Reserve TestGrowth Retardation, Chronic Renal FailureIdiopathic Short StatureLipodystrophyNoonan's SyndromePediatric Growth Hormone DeficiencyPrader-Willi SyndromeShort Bowel SyndromeShort Stature for AgeTurner Syndrome

Medical conditions associated with growth hormones:

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Excerpt from:

List of Growth hormones (human growth hormone) - Drugs.com

Human growth hormone (HGH) levels vary by age and sex.

HGH is released into the bloodstream by the pituitary gland. The primary function of HGH is tissue growth in children. In adults, HGH is responsible for cellular repair and regeneration. HGH also plays a role in many bodily functions and processes, primarily fat metabolism. Therefore, it plays a role in maintaining muscle tone, health, and fitness.

Your HGH levels vary by age. As you might imagine, HGH levels are highest in children.

The normal range for HGH level is typically:

As men age, there is a natural decline in HGH levels. HGH levels can and do fluctuate throughout the day. This is why doctors prefer to talk about normal HGH levels as a range, rather than a fixed ng/mL level.

Furthermore, because HGH levels in the blood vary at any given time, doctors prefer to establish the normal ranges of HGH by age based on IGF-1 levels. IGF-1 is another hormone. It is created by the liver and stimulates HGH production. IGF-1 levels are more constant than HGH levels and give a clear picture of ability to produce and release HGH.

The following chart (provided by LabCorp our testing facility) gives the normal IGF-1 for men by age.

AGE In Years

Male (ng/mL)

31 to 35

88246

36 to 40

83233

41 to 45

75216

46 to 50

67205

51 to 55

61200

56 to 60

54194

61 to 65

49188

66 to 70

47192

71 to 75

41179

76 to 80

37172

81 to 85

34165

86 to 90

32166

>90

Not established

Normal levels of human growth hormone (HGH) levels vary by age and sex.

Low HGH levels may indicate problems with your pituitary gland. Below normal HGH levels by age in men can result in a reduced sense of wellbeing, increased fat, increased risk of heart disease, and weakening muscles and bones.

While it is rarer than low HGH levels, some people do suffer from HGH levels that are too high. If your HGH levels are higher than normal, it can result in a rare condition known as acromegaly, in which patients have swelling of the hands and feet and altered facial features. Extremely high levels of HGH in children can cause gigantism, or growth to unusually tall stature. In almost all cases of acromegaly or gigantism, the above normal HGH levels are the result of a pituitary tumor.

HGH levels in women also vary by age just as they do in men. Again, we use IGF-1 levels to establish normal HGH levels in women by age. The following chart shows the normal IGF-1 levels in women by age.

AGE In Years

Female (ng/mL)

31 to 35

73243

36 to 40

69227

41 to 45

62204

46 to 50

57195

51 to 55

53190

56 to 60

46172

61 to 65

42169

66 to 70

38163

71 to 75

37165

76 to 80

35165

81 to 85

34172

86 to 90

34178

>90

Not established

HGH levels fluctuate throughout the day, so normal levels of HGH are expressed in a range, rather than a fixed level.

In women, HGH levels drop to their lowest after menopause. However, sometimes women who are still in their childbearing years, might require growth hormone therapy. What impact does growth hormone have on pregnancy? There have been some studies that indicate for women who are having trouble getting pregnant, growth hormone therapy may increase fertility. Once a woman becomes pregnant, her body automatically produces excessive HGH and IGF-1 for the developing fetus. Supplemental HGH is not recommended for pregnant women.

HGH levels decrease if you have a disease, injury, or genetic condition that impacts your pituitary glands ability to make HGH. HGH levels also decline naturally as men and women age. This natural drop in HGH as you grow older can result in age-related GHD.

Since your growth hormone levels can and do change throughout the day, instead of a test that measures the HGH level in your blood at any given time, we test for the level of IGF-1.

During the test a blood sample will be drawn from a vein in your arm. Since HGH levels fluctuate throughout the day, we do not test for HGH, but rather IGF-1. IGF-1 mirrors HGH excesses and deficiencies, but the level in the blood is stable throughout the day, making it a more useful indicator of average HGH levels than testing for HGH.

Before performing specific HGH testing, if the IGF-1 level is found to be normal for age and sex, growth hormone deficiency (GHD) can be ruled out, and more definitive testing is not necessary.

There could be some ways to naturally increase your HGH levels. Exercise, particularly strength training, or high intensity interval training can raise HGH levels. Here are some other ways that both men and women can naturally raise their HGH levels.

The above lifestyle changes could help keep your HGH level close to normal for your age and gender. However, if the results of your HGH or IGF-1 test indicate you have a growth hormone deficiency, or GHD, the only way that it can be treated is with hormone replacement therapy.

If your growth hormone level is determined to be below normal, depending on your age, gender and symptoms you will likely be prescribed growth hormone injections. Growth hormone injections are used to treat GHD in children and adults.

Growth hormone injections are only available with a doctors prescription. There are many anti-aging benefits of HGH replacement therapy. One of the main benefits of growth hormone replacement, is that it will improve your ability to burn fat and build lean muscle. This benefit alone will go a long way to making you look and feel younger.

However, the many benefits of HGH do not stop there. HGH therapy:

HGH therapy is a safe and effective way to treat lower than normal HGH levels.

Now that you know a bit more about normal and low HGH levels, why not contact us today, and find out more about the many life-changing benefits of HGH and other hormone replacement therapies.

See the original post:

What You Need to Know About Human Growth Hormone Levels

Selected Important Safety Information

Do not use Norditropin if: you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing (respiratory) problems; you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea; you have cancer or other tumors; you are allergic to somatropin or any of the ingredients in Norditropin; your healthcare provider tells you that you have certain types of eye problems caused by diabetes (diabetic retinopathy); you are a child with closed bone growth plates (epiphyses).

Indications and Usage

What is Norditropin (somatropin) injection?

Norditropin is a prescription medicine that contains human growth hormone and is used to treat:

Important Safety Information (contd)

Before taking Norditropin, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Norditropin may affect how other medicines work, and other medicines may affect how Norditropin works.

How should I use Norditropin?

What are the possible side effects of Norditropin? Norditropin may cause serious side effects, including:

The most common side effects of Norditropin include:

Pleaseclick herefor NorditropinPrescribing Information.

Norditropin is a prescription medication.

Novo Nordisk provides patient assistance for those who qualify. Please call 1-866-310-7549 to learn more about Novo Nordisk assistance programs.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800- FDA-1088.

Talk to your health care provider and find out if Norditropin is right for you or your child.

See the rest here:

Growth Hormone Therapy | Norditropin (somatropin) Injection

Igor Vovkovinskiy, the country's tallest person at 7-foot-8, died in Minnesota at the age of 38. His family says he died of heart disease. Haraz N. Ghanbari/AP hide caption

Igor Vovkovinskiy, the country's tallest person at 7-foot-8, died in Minnesota at the age of 38. His family says he died of heart disease.

ROCHESTER, Minn. Igor Vovkovinskiy, the tallest man in the United States, has died. He was 38.

His family said the Ukrainian-born Vovkovinskiy died of heart disease on Friday at the Mayo Clinic in Rochester. His mother, Svetlana Vovkovinska, an ICU nurse at Mayo, initially posted about his death on Facebook.

Vovkovinskiy came to the Mayo Clinic in 1989 as a child seeking treatment. A tumor pressing against his pituitary gland caused it to secrete abnormal levels of growth hormone. He grew to become the tallest man in the U.S. at 7 feet, 8.33 inches (2 meters, 34.5 centimeters) and ended up staying in Rochester.

His older brother, Oleh Ladan of Brooklyn Park, told the Star Tribune of Minneapolis that Vovkovinskiy was a celebrity when he arrived from Ukraine because of his size and the flickering Cold War of the late 1980s. But Ladan said Vovkovinskiy "would have rather lived a normal life than be known."

Vovkovinskiy met President Barack Obama during a health care reform rally in 2009, when the president noticed him near the stage wearing a T-shirt that read, "World's Biggest Obama Supporter." Ben Garvin/AP hide caption

Vovkovinskiy appeared on "The Dr. Oz Show" and was called out by President Barack Obama during a campaign rally in 2009, when the president noticed him near the stage wearing a T-shirt that read, "World's Biggest Obama Supporter." In 2013, he carried the Ukrainian contestant onto the stage to perform in the Eurovision Song Contest.

When he was 27, Vovkovinskiy traveled to New York City and was declared America's tallest living person by a Guinness World Records adjudicator on Oz's show. He edged out a sheriff's deputy in Virginia by one-third of an inch.

He issued a plea in 2012 to cover the estimated $16,000 cost for specially made shoes that wouldn't cause him crippling pain. At the time, he said he hadn't owned a pair for years that fit his size 26, 10E feet. Thousands donated more than double what he needed. Reebok provided the custom shoes for free.

Vovkovinskiy was born Sept. 8, 1982, in Bar, Ukraine, to Vovkovinska and Oleksandr Ladan, according to Ranfranz and Vine Funeral Home, which is holding a memorial service on Saturday. His father died earlier.

Continued here:

Igor Vovkovinskiy, Who At 7-Foot-8 Was The Tallest Man In The U.S., Has Died - NPR

Could good nutrition save people from developing severe COVID-19?

According to experts in the field, nutrition is the biggest coronavirus risk factor that not enough people are talking about.

We have two epidemics: obesity and COVID-19, said Dr. Mariela Glandt, a Harvard University and Columbia University trained endocrinologist and nutritionist who now lives in Israel and runs a clinic for diabetics in Ramat Aviv.

cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b' }).render('4c4d856e0e6f4e3d808bbc1715e132f6'); });

She said, As long as the pandemic is still going on, anyone who cares about their health should do everything they can to improve the risk factors that they control among them diet.

A poor diet, like the modern American diet, with its junk food, ultra-processed starches and cheap fats, causes metabolic dysfunction that can be a disaster when its combined with the coronavirus, Glandt wrote in an eBook titled How to Eat in the Time of COVID-19 that she recently published with Ross Wollen and Jessica Apple.

The book was published by ASweetLife, which describes itself as the Internets trusted authority on the art of living well with diabetes.

Severe COVID-19 hospitalization, treatment in an intensive care unit, mechanical ventilation and even death has been associated with higher body mass index, the Centers for Disease Control has said.

Specifically, obesity defined by BMI increases the odds of hospitalization by 76%, Boaz showed in a paper that is soon to be published but has not yet been peer reviewed. She said the likelihood of ICU admission increases by 67%, mechanical ventilation by 119% and death by 37% all according to recent studies.

Moreover, a study that was published in the peer-reviewed journal PLOS One at the end of last month showed that people with high sugar values but who were not diagnosed with diabetes were also at risk of severe COVID-19 morbidity or mortality.

The researchers from Hebrew University of Jerusalem, Meuhedet Health Services, Jerusalem College of Technology and Hadassah-University Medical Center conducted a retroactive study among all individuals over the age of 18 who were insured by Meuhedet and contracted the virus between March and October 2020.

Of the 37,121 people who tested positive, 707 of them had severe disease, including 244 who died.

THE NORMAL blood sugar level in an adult is 70 to 100 milligrams per deciliter (mg/dL) of blood sugar after an eight-hour fast. Patients with 105-125 mg/dL were 1.5 times more likely to have severe COVID than patients with sugar lower than 105. Patients with between 125-140 mg/dL were twice as likely to develop complications.

The aim of the study was to identify risk factors for severe coronavirus illness that can be treated ahead of time, explained Dr. Michal Shauly-Aharonov of the Jerusalem College of Technology.

Obesity, high blood pressure, diabetes and many forms of cardiovascular disease are symptoms of an underlying medical condition called insulin resistance, Glandt wrote in her book.

Insulin is the hormone that allows your body to utilize the glucose in the food that you eat. Normally, this is a healthy and natural process insulin levels rise when eating, and subside to very low levels between meals, Glandt explained. Insulin is a storage and growth hormone and it is critical that there be a balance between high and low levels.

But when you eat a diet full of sweets and starches, your insulin production can grow out of control. Eventually, your cells become resistant to insulin, dulling its effect, which just causes your body to produce even more of it, as your body struggles to move glucose [sugar] out of your blood and into your cells, she said.

High sugar levels mean there is no more room to store sugar in a persons cells and so the sugar stays in the blood. If a person stops bringing sugar into their body, their sugar level will decline.

Through her own clinic, she has managed to get 97% of clients off insulin through diet management. The average client loses eight kg. (18 lbs.) in the first six months. Moreover, some 65% of clients normalize their blood sugar to the extent that they are no longer considered diabetic.

She advocates for the ketogenic diet, which includes avoiding all seed oils, such as canola, soybean, sunflower and corn; avoiding all sugars; and keeping complex carbohydrates to a minimum.

Boaz, on the other hand, has said that a modified Mediterranean diet to achieve the right balance, which includes fish, nuts, hummus, tahini and refried beans, is high in fruits and vegetables, whole grains and olive oils and low in processed foods.

This particular pandemic highlighted the impact that obesity can have on the immune system, Boaz said.

She stressed that public health policy should be directed at improving diet quality, especially among youths who are much more likely to follow healthful practices if taught from an early age.

Logic would tell you, Boaz said, being adequately nourished and maintaining a healthy diet is always to your benefit.

More here:

Can what you eat save you from COVID-19? - The Jerusalem Post